1. Home
  2. BBWI vs PRAX Comparison

BBWI vs PRAX Comparison

Compare BBWI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBWI
  • PRAX
  • Stock Information
  • Founded
  • BBWI 1963
  • PRAX 2015
  • Country
  • BBWI United States
  • PRAX United States
  • Employees
  • BBWI N/A
  • PRAX N/A
  • Industry
  • BBWI Clothing/Shoe/Accessory Stores
  • PRAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBWI Consumer Discretionary
  • PRAX Health Care
  • Exchange
  • BBWI Nasdaq
  • PRAX Nasdaq
  • Market Cap
  • BBWI 5.0B
  • PRAX 4.0B
  • IPO Year
  • BBWI N/A
  • PRAX 2020
  • Fundamental
  • Price
  • BBWI $15.52
  • PRAX $189.56
  • Analyst Decision
  • BBWI Buy
  • PRAX Strong Buy
  • Analyst Count
  • BBWI 18
  • PRAX 13
  • Target Price
  • BBWI $28.28
  • PRAX $228.69
  • AVG Volume (30 Days)
  • BBWI 10.0M
  • PRAX 857.5K
  • Earning Date
  • BBWI 11-20-2025
  • PRAX 11-05-2025
  • Dividend Yield
  • BBWI 5.14%
  • PRAX N/A
  • EPS Growth
  • BBWI N/A
  • PRAX N/A
  • EPS
  • BBWI 3.30
  • PRAX N/A
  • Revenue
  • BBWI $7,354,000,000.00
  • PRAX $7,463,000.00
  • Revenue This Year
  • BBWI $4.09
  • PRAX N/A
  • Revenue Next Year
  • BBWI $2.75
  • PRAX $44.43
  • P/E Ratio
  • BBWI $4.72
  • PRAX N/A
  • Revenue Growth
  • BBWI N/A
  • PRAX 364.98
  • 52 Week Low
  • BBWI $14.28
  • PRAX $26.70
  • 52 Week High
  • BBWI $41.87
  • PRAX $206.71
  • Technical
  • Relative Strength Index (RSI)
  • BBWI 17.50
  • PRAX 58.41
  • Support Level
  • BBWI $14.28
  • PRAX $160.11
  • Resistance Level
  • BBWI $22.43
  • PRAX $197.50
  • Average True Range (ATR)
  • BBWI 0.82
  • PRAX 16.19
  • MACD
  • BBWI -0.74
  • PRAX -4.67
  • Stochastic Oscillator
  • BBWI 12.60
  • PRAX 73.49

About BBWI Bath & Body Works Inc.

Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 5% of sales from international markets in fiscal 2024. For fiscal 2024, 76% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,800 retail stores), similar to 2023 levels, as consumer shopping patterns remained to normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like hair and laundry.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Share on Social Networks: